OCSAW
Oculis Holding AGPrice
Daily candles with volume.
Signal stack
Where each data set points today.
- Short sellersBUILDING
Short interest +111.0% to 17.4K shares. 2.5 days to cover, ≈0.0% of shares.
Who's buying
13F| Top holder | Shares | Value |
|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 140,000 | $700.0K |
| JANE STREET GROUP, LLC | 45,702 | $228.5K |
| LMR Partners LLP | 39,949 | $199.7K |
| D. E. Shaw & Co., Inc. | 34,716 | $173.6K |
| UBS Group AG | 300 | $1.5K |
Quarterly 13F filings are due 45 days after each quarter ends.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $157.6K |
| Next Q | — | — | — | $146.0K |
| Current FY | — | — | — | $878.0K |
| Next FY | — | — | — | $4.1M |
Short side
FINRA· Oct 15, 2026SecBot reports
2 filings · 1 bullish · 0 bearish · 1 neutral- NEUTRAL 6-KMay 11, 2026
Oculis reported Q1 2026 results with a net loss of CHF 28.9 million ($36.8M), improved from CHF…
The stock is a binary catalyst play on OCS-01 DIAMOND Phase 3 data in June 2026. With $277.6M cash runway into 2H 2029, the company is well-funded through multiple readouts. Monitor the OCS-01…
- BULLISH 6-KApr 21, 2026
Oculis Holding AG reported a transformative 2025 marked by significant clinical progress across…
Monitor June 2026 for topline results from the DIAMOND-1 and DIAMOND-2 trials for OCS-01, which could be a major catalyst for the stock. The company's strong cash position from recent financings…
All OCSAW filing & press-release reports (2)
- 6-K reportMay 11, 2026
- 6-K reportApr 21, 2026